Bristol Myers Commits $11.1B in Strategic Bet on BioNTech’s Next-Gen Cancer Immunotherapy

Princeton, NJ, June 2, 2025 (Reuters) -- Bristol Myers Squibb will pay up to $11.1 billion to co-develop BioNTech's next-generation cancer immunotherapy, BNT327, targeting solid tumors through a novel dual-action approach. The deal gives BioNTech vital resources to scale its oncology pipeline and challenges Merck’s Keytruda-dominated market. It also reflects a broader industry shift toward bispecific antibody technologies in cancer treatment.

Read full article here.